{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:13:23Z","timestamp":1787948003892,"version":"build-2784847793"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T00:00:00Z","timestamp":1513728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["HTA 08\/53\/31"],"award-info":[{"award-number":["HTA 08\/53\/31"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40273-017-0600-7","type":"journal-article","created":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T09:36:38Z","timestamp":1513762598000},"page":"451-465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Mapping the Paediatric Quality of Life Inventory (PedsQL\u2122) Generic Core Scales onto the Child Health Utility Index\u20139 Dimension (CHU-9D) Score for Economic Evaluation in Children"],"prefix":"10.1007","volume":"36","author":[{"name":"On behalf of the PREDNOS Trial Team","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tosin","family":"Lambe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5462-1158","authenticated-orcid":false,"given":"Emma","family":"Frew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie J.","family":"Ives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Woolley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Cummins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Brettell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma N.","family":"Barsoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J. A.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,20]]},"reference":[{"key":"600_CR1","doi-asserted-by":"publisher","first-page":"S217","DOI":"10.1097\/00005650-198903001-00018","volume":"27","author":"DL Patrick","year":"1989","unstructured":"Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989:27:S217\u201332.","journal-title":"Med Care"},{"key":"600_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00019053-200017010-00002","volume":"17","author":"SJ Coons","year":"2000","unstructured":"Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality-of-life instruments. Pharmacoeconomics. 2000;17:13\u201335.","journal-title":"Pharmacoeconomics"},{"key":"600_CR3","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/0272989X8900900209","volume":"9","author":"A Mehrez","year":"1989","unstructured":"Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making. 1989;9:142\u20139.","journal-title":"Med Decis Making"},{"key":"600_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0954-6111(06)80166-6","volume":"85","author":"PW Jones","year":"1991","unstructured":"Jones PW, Quirk F, Baveystock C. The St George\u2019s respiratory questionnaire. Respir Med. 1991;85:25\u201331.","journal-title":"Respir Med"},{"key":"600_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10198-009-0168-z","volume":"11","author":"JE Brazier","year":"2010","unstructured":"Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11:215\u201325.","journal-title":"Eur J Health Econ"},{"key":"600_CR6","first-page":"167","volume-title":"Cost-effectiveness in health and medicine","author":"D Feeny","year":"2017","unstructured":"Feeny D, Krahn M, Prosser LA, Salomon J. Valuing health outcomes. In: Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. Cost-effectiveness in health and medicine. 2nd ed. New York: Oxford University; 2017. p. 167\u2013200.","edition":"2"},{"key":"600_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780198725923.001.0001","volume-title":"Measuring and valuing health benefits for economic evaluation","author":"JE Brazier","year":"2016","unstructured":"Brazier JE, Ratcliffe J, Salomon JA, Tsuchiya A. Measuring and valuing health benefits for economic evaluation. 2nd ed. Oxford: Oxford University; 2016.","edition":"2"},{"key":"600_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/hec.4730020108","volume":"2","author":"K Gerard","year":"1993","unstructured":"Gerard K, Mooney G. QALY league tables: handle with care. Health Econ. 1993;2:59\u201364.","journal-title":"Health Econ"},{"key":"600_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/hec.4730030205","volume":"3","author":"E Nord","year":"1994","unstructured":"Nord E. The QALY\u2014a measure of social value rather than individual utility? Health Econ. 1994;3:89\u201393.","journal-title":"Health Econ"},{"key":"600_CR10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/1049732309358328","volume":"20","author":"KJ Stevens","year":"2010","unstructured":"Stevens KJ. Working with children to develop dimensions for a preference-based, generic, pediatric, health-related quality-of-life measure. Qual Health Res. 2010;20:340\u201351.","journal-title":"Qual Health Res"},{"key":"600_CR11","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1542\/peds.2004-2127","volume":"115","author":"I Griebsch","year":"2005","unstructured":"Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics. 2005;115:e600\u201314.","journal-title":"Pediatrics"},{"key":"600_CR12","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","volume":"39","author":"JW Varni","year":"2001","unstructured":"Varni JW, Seid M, Kurtin PS. PedsQL\u2122 4.0: reliability and validity of the Pediatric Quality of Life Inventory\u2122 version 4.0 Generic Core Scales in healthy and patient populations. Med Care. 2001;39:800\u201312.","journal-title":"Med Care"},{"key":"600_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1136\/adc.84.3.205","volume":"84","author":"C Eiser","year":"2001","unstructured":"Eiser C, Morse R. A review of measures of quality of life for children with chronic illness. Arch Dis Child. 2001;84:205\u201311.","journal-title":"Arch Dis Child"},{"key":"600_CR14","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2165\/11599120-000000000-00000","volume":"30","author":"K Stevens","year":"2012","unstructured":"Stevens K. Valuation of the Child Health Utility 9D Index. Pharmacoeconomics. 2012;30:729\u201347.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"600_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40273-016-0476-y","volume":"35","author":"C Mpundu-Kaambwa","year":"2017","unstructured":"Mpundu-Kaambwa C, Chen G, Russo R, Stevens K, Petersen KD, Ratcliffe J. Mapping CHU9D Utility Scores from the PedsQL\u2122 4.0 SF-15. Pharmacoeconomics. 2017;35(4):453\u201367.","journal-title":"Pharmacoeconomics"},{"key":"600_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.socscimed.2016.03.042","volume":"157","author":"J Ratcliffe","year":"2016","unstructured":"Ratcliffe J, Huynh E, Chen G, Stevens K, Swait J, Brazier J, Sawyer M, Roberts R, Flynn T. Valuing the Child Health Utility 9D: using profile case best worst scaling methods to develop a new adolescent specific scoring algorithm. Soc Sci Med. 2016;157:48\u201359.","journal-title":"Soc Sci Med"},{"key":"600_CR17","unstructured":"Webb N, Trompeter R, Cummins C, Wheatley K, Frew E, Kaambwa B, et al. Long-term tapering versus standard prednisolone (steroid) therapy for the treatment of the initial episode of childhood nephrotic syndrome: national multicentre randomised double blind trial. National Institute for Health Research Health Technology Assessment programme. 2014; ISRCTN16645249. \n                    https:\/\/www.birmingham.ac.uk\/Documents\/college-mds\/trials\/bctu\/prednos\/PREDNOSProtocolV22.pdf\n                    \n                  . Accessed 13 Dec 2017."},{"key":"600_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-11-151","volume":"11","author":"H Dakin","year":"2013","unstructured":"Dakin H. Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database. Health Qual Life Outcomes. 2013;11:1.","journal-title":"Health Qual Life Outcomes"},{"key":"600_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12887-015-0526-1","volume":"15","author":"EJ Frew","year":"2015","unstructured":"Frew EJ, Pallan M, Lancashire E, Hemming K, Adab P. Is utility-based quality of life associated with overweight in children? Evidence from the UK WAVES randomised controlled study. BMC Pediatr. 2015;15:211.","journal-title":"BMC Pediatr"},{"key":"600_CR20","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1186\/s12889-015-1800-8","volume":"15","author":"P Adab","year":"2015","unstructured":"Adab P, Pallan MJ, Lancashire ER, Hemming K, Frew E, Griffin T, et al. A cluster-randomised controlled trial to assess the effectiveness and cost-effectiveness of a childhood obesity prevention programme delivered through schools, targeting 6\u20137\u00a0year old children: the WAVES study protocol. BMC Public Health. 2015;15:488.","journal-title":"BMC Public Health."},{"key":"600_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11136-012-0119-5","volume":"22","author":"AG Canaway","year":"2013","unstructured":"Canaway AG, Frew EJ. Measuring preference-based quality of life in children aged 6\u20137\u00a0years: a comparison of the performance of the CHU-9D and EQ-5D-Y\u2014the WAVES Pilot Study. Qual Life Res. 2013;22:173\u201383.","journal-title":"Qual Life Res"},{"key":"600_CR22","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jval.2012.07.011","volume":"15","author":"K Stevens","year":"2012","unstructured":"Stevens K, Ratcliffe J. Measuring and valuing health benefits for economic evaluation in adolescence: an assessment of the practicality and validity of the Child Health Utility 9D in the Australian adolescent population. Value Health. 2012;15:1092\u20139.","journal-title":"Value Health"},{"key":"600_CR23","unstructured":"University of Sheffield, School of Health and Related Research (ScHARR). A brief overview of Child Health Utility 9D (CHU9D). 2017. \n                    https:\/\/www.sheffield.ac.uk\/scharr\/sections\/heds\/mvh\/paediatric\/about-chu9d\n                    \n                  . Accessed 27 Sep 2017."},{"key":"600_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1367\/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2","volume":"3","author":"JW Varni","year":"2003","unstructured":"Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL\u2122 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr. 2003;3:329\u201341.","journal-title":"Ambul Pediatr"},{"key":"600_CR25","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1137\/0717073","volume":"17","author":"GH Golub","year":"1980","unstructured":"Golub GH, Van Loan CF. An analysis of the total least squares problem. SIAM J Numer Anal. 1980;17:883\u201393.","journal-title":"SIAM J Numer Anal"},{"key":"600_CR26","doi-asserted-by":"crossref","unstructured":"Crawley MJ. Generalized linear models. In: The R book. 2nd ed. Chichester: Wiley; 2007.","DOI":"10.1002\/9780470515075.ch18"},{"key":"600_CR27","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1097\/01.CCM.0000275267.64078.B0","volume":"35","author":"AA Kramer","year":"2007","unstructured":"Kramer AA, Zimmerman JE. Assessing the calibration of mortality benchmarks in critical care: the Hosmer-Lemeshow test revisited. Crit Care Med. 2007;35:2052\u20136.","journal-title":"Crit Care Med"},{"key":"600_CR28","volume-title":"Applied logistic regression","author":"DW Hosmer Jr","year":"2004","unstructured":"Hosmer DW Jr, Lemeshow S. Applied logistic regression. New York: Wiley; 2004."},{"key":"600_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2307\/1907382","volume":"26","author":"J Tobin","year":"1958","unstructured":"Tobin J. Estimation of relationships for limited dependent variables. Econometrica. 1958:26:24\u201336.","journal-title":"Econometrica"},{"key":"600_CR30","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/BF01206278","volume":"16","author":"A Reynolds","year":"1991","unstructured":"Reynolds A, Shonkwiler J. Testing and correcting for distributional misspecifications in the Tobit model: an application of the information matrix test. Empir Econ. 1991;16:313\u201323.","journal-title":"Empir Econ"},{"key":"600_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12955-014-0163-7","volume":"12","author":"I Khan","year":"2014","unstructured":"Khan I, Morris S. A non-linear beta-binomial regression model for mapping EORTC QLQ-C30 to the EQ-5D-3L in lung cancer patients: a comparison with existing approaches. Health Qual Life Outcomes. 2014;12:163.","journal-title":"Health Qual Life Outcomes"},{"key":"600_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-017-0049-9","author":"R Crott","year":"2017","unstructured":"Crott R. Direct mapping of the QLQ-C30 to EQ-5D preferences: a comparison of regression methods. Pharmacoeconomics. 2017. \n                    https:\/\/doi.org\/10.1007\/s41669-017-0049-9\n                    \n                  .","journal-title":"Pharmacoeconomics."},{"key":"600_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/0272989X15578127","volume":"36","author":"G Chen","year":"2016","unstructured":"Chen G, Khan MA, Iezzi A, Ratcliffe J, Richardson J. Mapping between 6 multiattribute utility instruments. Med Decis Making. 2016;36:160\u201375.","journal-title":"Med Decis Making"},{"key":"600_CR34","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s11136-009-9499-6","volume":"18","author":"N Payakachat","year":"2009","unstructured":"Payakachat N, Summers KH, Pleil AM, Murawski MM, Thomas J, Jennings K, et al. Predicting EQ-5D utility scores from the 25-item National Eye Institute Vision Function Questionnaire (NEI-VFQ 25) in patients with age-related macular degeneration. Qual Life Res. 2009;18:801\u201313.","journal-title":"Qual Life Res"},{"key":"600_CR35","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40273-014-0153-y","volume":"32","author":"KA Khan","year":"2014","unstructured":"Khan KA, Petrou S, Rivero-Arias O, Walters SJ, Boyle SE. Mapping EQ-5D utility scores from the PedsQL\u2122 generic core scales. Pharmacoeconomics. 2014;32:693\u2013706.","journal-title":"Pharmacoeconomics"},{"key":"600_CR36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.ijforecast.2006.03.001","volume":"22","author":"RJ Hyndman","year":"2006","unstructured":"Hyndman RJ, Koehler AB. Another look at measures of forecast accuracy. Int J Forecast. 2006;22:679\u201388.","journal-title":"Int J Forecast"},{"key":"600_CR37","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40273-015-0312-9","volume":"33","author":"S Petrou","year":"2015","unstructured":"Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, Gray A. The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: explanation and elaboration. Pharmacoeconomics. 2015;33:993\u20131011.","journal-title":"Pharmacoeconomics"},{"key":"600_CR38","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3109\/07853890109002088","volume":"33","author":"M Drummond","year":"2001","unstructured":"Drummond M. Introducing economic and quality of life measurements into clinical studies. Ann Med. 2001;33:344\u20139.","journal-title":"Ann Med"},{"key":"600_CR39","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.socscimed.2004.08.034","volume":"60","author":"CA Marra","year":"2005","unstructured":"Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med. 2005;60:1571\u201382.","journal-title":"Soc Sci Med"},{"issue":"4","key":"600_CR40","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s11136-015-1218-x","volume":"25","author":"NR Boyer","year":"2016","unstructured":"Boyer NR, Miller S, Connolly P, McIntosh E. Paving the way for the use of the SDQ in economic evaluations of school-based population health interventions: an empirical analysis of the external validity of SDQ mapping algorithms to the CHU9D in an educational setting. Qual Life Res. 2016;25(4):913\u201323.","journal-title":"Qual Life Res"},{"issue":"2","key":"600_CR41","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11136-013-0494-6","volume":"23","author":"G Furber","year":"2014","unstructured":"Furber G, Segal L, Leach M, Cocks J. Mapping scores from the Strengths and Difficulties Questionnaire (SDQ) to preference-based utility values. Qual Life Res. 2014;23(2):403\u201311.","journal-title":"Qual Life Res"},{"key":"600_CR42","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12955-014-0134-z","volume":"12","author":"G Chen","year":"2014","unstructured":"Chen G, Stevens K, Rowen D, Ratcliffe J. From KIDSCREEN-10 to CHU9D: creating a unique mapping algorithm for application in economic evaluation. Health Qual Life Outcomes. 2014;12:134.","journal-title":"Health Qual Life Outcomes"},{"key":"600_CR43","unstructured":"NICE. Guide to the methods of technology appraisal 2013. NICE guideline. PMG9. 2013. \n                    https:\/\/www.nice.org.uk\/process\/pmg9\n                    \n                  . Accessed 12 Dec 2017."},{"key":"600_CR44","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/02841860410029357","volume":"43","author":"Essen Lv","year":"2004","unstructured":"Lv Essen. Proxy ratings of patient quality of life factors related to patient\u2013proxy agreement. Acta Oncol. 2004;43:229\u201334.","journal-title":"Acta Oncol"},{"key":"600_CR45","volume-title":"Using proxies to assess quality of life: a review of the issues and challenges","author":"S Rand","year":"2015","unstructured":"Rand S, Caiels J. Using proxies to assess quality of life: a review of the issues and challenges. Canterbury: QORU, University of Kent; 2015."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-017-0600-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0600-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0600-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T09:39:32Z","timestamp":1551951572000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-017-0600-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,20]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1007\/s40273-017-0600-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,20]]},"assertion":[{"value":"20 December 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The study was approved by the North West\u2013GM Central Research Ethics Committee (reference: 12\/NW\/0766).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), NIHR or the Department of Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Department of Health Disclaimer"}},{"value":"NJAW has served on Advisory Boards within the past 5\u00a0years for Abbvie, Alexion, AMAG, Astellas, Raptor, Takeda and UCB. These have been related to the design and conduct of early-phase trials in childhood kidney disease. None has been related to the treatment of corticosteroid-sensitive nephrotic syndrome. TL, EF, NJI, RLW, EAB, ENB, and CC declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Written informed consent was obtained from parents\/guardians of participants and written assent was obtained from participants of appropriate age.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}